Yaara Zwang, Ph.D. - Publications

Affiliations: 
2009 BIR Biological Regulation Weizmann Institute of Science, Rehovot, Israel 
Area:
General Biology, Cell Biology

24 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Jacob Berger A, Gigi E, Kupershmidt L, Meir Z, Gavert N, Zwang Y, Prior A, Gilad S, Harush U, Haviv I, Stemmer SM, Blum G, Merquiol E, Mardamshina M, Kaminski Strauss S, et al. IRS1 phosphorylation underlies the non-stochastic probability of cancer cells to persist during EGFR inhibition therapy. Nature Cancer. 2: 1055-1070. PMID 35121883 DOI: 10.1038/s43018-021-00261-1  0.331
2020 Ben-Hamo R, Jacob Berger A, Gavert N, Miller M, Pines G, Oren R, Pikarsky E, Benes CH, Neuman T, Zwang Y, Efroni S, Getz G, Straussman R. Predicting and affecting response to cancer therapy based on pathway-level biomarkers. Nature Communications. 11: 3296. PMID 32620799 DOI: 10.1038/S41467-020-17090-Y  0.308
2017 Zwang Y, Jonas O, Chen C, Rinne ML, Doench JG, Piccioni F, Tan L, Huang HT, Wang J, Ham YJ, O'Connell J, Bhola P, Doshi M, Whitman M, Cima M, et al. Synergistic interactions with PI3K inhibition that induce apoptosis. Elife. 6. PMID 28561737 DOI: 10.7554/Elife.24523  0.375
2017 Tarcic O, Granit RZ, Pateras IS, Masury H, Maly B, Zwang Y, Yarden Y, Gorgoulis VG, Pikarsky E, Ben-Porath I, Oren M. RNF20 and histone H2B ubiquitylation exert opposing effects in Basal-Like versus luminal breast cancer. Cell Death and Differentiation. PMID 28157208 DOI: 10.1038/Cdd.2016.126  0.515
2015 Baratta MG, Schinzel AC, Zwang Y, Bandopadhayay P, Bowman-Colin C, Kutt J, Curtis J, Piao H, Wong LC, Kung AL, Beroukhim R, Bradner JE, Drapkin R, Hahn WC, Liu JF, et al. An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 112: 232-7. PMID 25535366 DOI: 10.1073/Pnas.1422165112  0.327
2015 Zwang Y, Chen C, Hahn WC. Abstract C73: A drug-modifier whole-genome shRNA screen identifies novel synthetic lethal interactions with PI3K inhibition in breast cancer Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C73  0.373
2014 Shao DD, Xue W, Krall EB, Bhutkar A, Piccioni F, Wang X, Schinzel AC, Sood S, Rosenbluh J, Kim JW, Zwang Y, Roberts TM, Root DE, Jacks T, Hahn WC. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell. 158: 171-84. PMID 24954536 DOI: 10.1016/J.Cell.2014.06.004  0.393
2012 Lovejoy CA, Li W, Reisenweber S, Thongthip S, Bruno J, de Lange T, De S, Petrini JH, Sung PA, Jasin M, Rosenbluh J, Zwang Y, Weir BA, Hatton C, Ivanova E, et al. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. Plos Genetics. 8: e1002772. PMID 22829774 DOI: 10.1371/Journal.Pgen.1002772  0.331
2012 Zwang Y, Oren M, Yarden Y. Consistency test of the cell cycle: roles for p53 and EGR1. Cancer Research. 72: 1051-4. PMID 22315347 DOI: 10.1158/0008-5472.Can-11-3382  0.523
2012 Tarcic G, Avraham R, Pines G, Amit I, Shay T, Lu Y, Zwang Y, Katz M, Ben-Chetrit N, Jacob-Hirsch J, Virgilio L, Rechavi G, Mavrothalassitis G, Mills GB, Domany E, et al. EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 26: 1582-92. PMID 22198386 DOI: 10.1096/Fj.11-194654  0.608
2011 Zwang Y, Sas-Chen A, Drier Y, Shay T, Avraham R, Lauriola M, Shema E, Lidor-Nili E, Jacob-Hirsch J, Amariglio N, Lu Y, Mills GB, Rechavi G, Oren M, Domany E, et al. Two phases of mitogenic signaling unveil roles for p53 and EGR1 in elimination of inconsistent growth signals. Molecular Cell. 42: 524-35. PMID 21596316 DOI: 10.1016/J.Molcel.2011.04.017  0.538
2010 Pines G, Huang PH, Zwang Y, White FM, Yarden Y. EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism. Oncogene. 29: 5850-60. PMID 20676128 DOI: 10.1038/Onc.2010.313  0.654
2010 Avraham R, Sas-Chen A, Manor O, Steinfeld I, Shalgi R, Tarcic G, Bossel N, Zeisel A, Amit I, Zwang Y, Enerly E, Russnes HG, Biagioni F, Mottolese M, Strano S, et al. EGF decreases the abundance of microRNAs that restrain oncogenic transcription factors. Science Signaling. 3: ra43. PMID 20516477 DOI: 10.1126/Scisignal.2000876  0.609
2009 Zwang Y, Yarden Y. Systems biology of growth factor-induced receptor endocytosis. Traffic (Copenhagen, Denmark). 10: 349-63. PMID 19183301 DOI: 10.1111/J.1600-0854.2008.00870.X  0.65
2007 Shtiegman K, Kochupurakkal BS, Zwang Y, Pines G, Starr A, Vexler A, Citri A, Katz M, Lavi S, Ben-Basat Y, Benjamin S, Corso S, Gan J, Yosef RB, Giordano S, et al. Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling. Oncogene. 26: 6968-78. PMID 17486068 DOI: 10.1038/Sj.Onc.1210503  0.721
2007 Zwang Y, Yarden Y. Growth factor signalling: ample opportunities for pharmaceutical interventions in oncology European Journal of Cancer, Supplement. 5: 427-429. DOI: 10.1016/S1359-6349(07)70086-1  0.517
2006 Zwang Y, Yarden Y. p38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy. The Embo Journal. 25: 4195-206. PMID 16932740 DOI: 10.1038/Sj.Emboj.7601297  0.644
2006 Oved S, Mosesson Y, Zwang Y, Santonico E, Shtiegman K, Marmor MD, Kochupurakkal BS, Katz M, Lavi S, Cesareni G, Yarden Y. Conjugation to Nedd8 instigates ubiquitylation and down-regulation of activated receptor tyrosine kinases. The Journal of Biological Chemistry. 281: 21640-51. PMID 16735510 DOI: 10.1074/Jbc.M513034200  0.688
2005 Rubin C, Zwang Y, Vaisman N, Ron D, Yarden Y. Phosphorylation of carboxyl-terminal tyrosines modulates the specificity of Sprouty-2 inhibition of different signaling pathways. The Journal of Biological Chemistry. 280: 9735-44. PMID 15637081 DOI: 10.1074/Jbc.M408308200  0.65
2004 Amit I, Yakir L, Katz M, Zwang Y, Marmor MD, Citri A, Shtiegman K, Alroy I, Tuvia S, Reiss Y, Roubini E, Cohen M, Wides R, Bacharach E, Schubert U, et al. Tal, a Tsg101-specific E3 ubiquitin ligase, regulates receptor endocytosis and retrovirus budding. Genes & Development. 18: 1737-52. PMID 15256501 DOI: 10.1101/Gad.294904  0.711
2003 Shelly M, Mosesson Y, Citri A, Lavi S, Zwang Y, Melamed-Book N, Aroeti B, Yarden Y. Polar expression of ErbB-2/HER2 in epithelia. Bimodal regulation by Lin-7. Developmental Cell. 5: 475-86. PMID 12967566 DOI: 10.1016/J.Devcel.2003.08.001  0.707
2003 Mosesson Y, Shtiegman K, Katz M, Zwang Y, Vereb G, Szollosi J, Yarden Y. Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation. The Journal of Biological Chemistry. 278: 21323-6. PMID 12719435 DOI: 10.1074/Jbc.C300096200  0.685
2003 Rubin C, Litvak V, Medvedovsky H, Zwang Y, Lev S, Yarden Y. Sprouty fine-tunes EGF signaling through interlinked positive and negative feedback loops. Current Biology : Cb. 13: 297-307. PMID 12593795 DOI: 10.1016/S0960-9822(03)00053-8  0.737
2002 Goldberg Z, Vogt Sionov R, Berger M, Zwang Y, Perets R, Van Etten RA, Oren M, Taya Y, Haupt Y. Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation. The Embo Journal. 21: 3715-27. PMID 12110584 DOI: 10.1093/Emboj/Cdf384  0.359
Show low-probability matches.